
Top Big Pharma Stocks: Our 5 Best Stock Picks for July 2026
Five big pharma stocks are ranked in a countdown, comparing specialty franchises, profitability, valuation, growth and earnings consistency for July 2026.
Every article, report, and earnings note where JNJ appears.

Five big pharma stocks are ranked in a countdown, comparing specialty franchises, profitability, valuation, growth and earnings consistency for July 2026.

Three medical-device stocks are ranked by investment quality, with women’s health, orthopedics, robotics, and diversified MedTech driving the countdown.

Eli Lilly's next move looks less like a pipeline trade and more like an access trade. Demand was never the problem; broader PBM coverage and expected Medicare access starting July 1 make the revenue conversion story more immediate.

Healthcare’s leadership over tech and semis looks less like a defensive flinch and more like a valuation message from a still-hawkish market. With rates staying restrictive, investors are rewarding nearer-term earnings durability and demanding a higher bar for crowded long-duration growth.

Our seven-stock Dividend Kings countdown spans industrials, healthcare, beverages, restaurants and household staples, with four lower-ranked names available in the free portion.

A seven-stock countdown spans beverages, restaurants, biopharmaceuticals and consumer staples, showing how dividend growth can blend income, defensiveness and earnings durability.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate JNJ ReportCancel anytime